Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | NTRK1 act mut |
| Gene Variant Detail | |
| Relevant Treatment Approaches |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| NTRK1 act mut | Advanced Solid Tumor | predicted - sensitive | Selitrectinib | Preclinical | Actionable | In a preclinical study, a cell line oncogenic mouse model expressing a constitutively active NTRK1 mutation demonstrated decreased phosphorylation of Ntrk1 and inhibition of tumor growth when treated with Selitrectinib (LOXO-195) (PMID: 28578312). | 28578312 | |
| NTRK1 act mut | Advanced Solid Tumor | predicted - sensitive | Larotrectinib | Preclinical | Actionable | In a preclinical study, a cell line oncogenic mouse model expressing a constitutively active NTRK1 mutation demonstrated decreased phosphorylation of Ntrk1 and inhibition of tumor growth when treated with Vitrakvi (larotrectinib) (PMID: 28578312). | 28578312 |